Cart
sales@molnova.com
MSNBA
CAS No. 852702-51-3
MSNBA( —— )
Catalog No. M37026 CAS No. 852702-51-3
MSNBA is a selective and potent inhibitor of fructose transport through GLUT5 and also acts as a probe of the GLUT5 transporter. MSNBA inhibited GLUT5 fructose uptake in MCF7 cells with KI of 3.2±0.4 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 29 | Get Quote |
|
| 25MG | 43 | Get Quote |
|
| 50MG | 70 | Get Quote |
|
| 100MG | 110 | Get Quote |
|
| 500MG | 267 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMSNBA
-
NoteResearch use only, not for human use.
-
Brief DescriptionMSNBA is a selective and potent inhibitor of fructose transport through GLUT5 and also acts as a probe of the GLUT5 transporter. MSNBA inhibited GLUT5 fructose uptake in MCF7 cells with KI of 3.2±0.4 μM.
-
DescriptionMSNBA is a specific inhibitor of GLUT5 fructose transport in proteoliposomes. MSNBA competitively inhibits GLUT5 fructose uptake with a KI of 3.2±0.4?μM in MCF7 cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptortransporter
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number852702-51-3
-
Formula Weight336.32
-
Molecular FormulaC14H12N2O6S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (297.34 mM; Ultrasonic )
-
SMILESO=N(=O)C1=CC(=CC=C1NC2=CC=C3OCOC3=C2)S(=O)(=O)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. George Thompson AM, et al. Discovery of a specific inhibitor of human GLUT5 by virtual screening and in vitro transport evaluation. Sci Rep. 2016 Apr 14;6:24240.
molnova catalog
related products
-
Pyrazinamine
Pyrazinamine is a synthetic intermediate that can be used in a variety of scientific research applications, including as a synthetic reagent and as a biochemical and physiological reagent.
-
AZD0780
AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.
-
Niraparib Tosylate M...
Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.
